Search results for "moth"

showing 10 items of 2617 documents

Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: Recommended schedule for expected activity…

2018

// Gemma Bruera 1, 2 , Silvia Massacese 3 , Stefania Candria 1 , Antonio Galvano 4 , Rosa Manetta 5 , Aldo Victor Giordano 5 , Sergio Carducci 5 , Alessandra Di Sibio 5 , Eugenio Ciacco 3 , Antonio Russo 4 , Enrico Ricevuto 1, 2 and on behalf of Oncology Network ASL1 Abruzzo, Italy 1 Oncology Territorial Care Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L’Aquila, L’Aquila, Italy 2 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy 3 Pharmacy Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L’Aquila, Italy 4 Medical Oncology Unit, Department of Surgical, Oncological and Stomatological Sciences, Univers…

0301 basic medicinemedicine.medical_specialtyFOLFIRINOXPhase II studyPhases of clinical research03 medical and health sciences0302 clinical medicineFIr/FOxFIr/FOx; First-line; Metastatic pancreatic ductal adenocarcinoma; Phase II study; Triplet chemotherapyInternal medicinemedicineMucositisPerformance statusbusiness.industryFirst-linemedicine.diseaseGemcitabineOxaliplatinIrinotecan030104 developmental biologyMetastatic pancreatic ductal adenocarcinomaOncology030220 oncology & carcinogenesisLiver functionTriplet chemotherapybusinessResearch Papermedicine.drug
researchProduct

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: Predictive value of DNA-PK and phosphorylated ACC

2016

// Francesco Perrone 1,* , Gustavo Baldassarre 2,* , Stefano Indraccolo 3,* , Simona Signoriello 4 , Gennaro Chiappetta 1 , Franca Esposito 5 , Gabriella Ferrandina 6 , Renato Franco 1,15 , Delia Mezzanzanica 7 , Maura Sonego 2 , Elisabetta Zulato 3 , Gian F. Zannoni 6 , Vincenzo Canzonieri 2 , Giovanni Scambia 6 , Roberto Sorio 2 , Antonella Savarese 8 , Enrico Breda 9 , Paolo Scollo 10 , Antonella Ferro 11 , Stefano Tamberi 12 , Antonio Febbraro 13 , Donato Natale 14 , Massimo Di Maio 1,16 , Daniela Califano 1 , Giosue  Scognamiglio 1 , Domenica Lorusso 7 , Silvana Canevari 7 , Simona Losito 1 , Ciro Gallo 4,** and Sandro Pignata 1,** 1 Istituto Nazionale per lo Studio e la Cura dei Tumor…

0301 basic medicinemedicine.medical_specialtyLiposomal Doxorubicinovarian cancer; phase 3 clinical trial; predictive factors; pACC; DNA-PKDNA-Activated Protein KinaseDisease-Free Survivalpredictive factorDNA-PK03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOvarian cancerPhase 3 clinical trialAntineoplastic Combined Chemotherapy ProtocolsOverall survivalMedicineHumansDNA-PK; ovarian cancer; pACC; phase 3 clinical trial; predictive factorsGynecologyOvarian NeoplasmsAdvanced ovarian cancerphase 3 clinical trialbusiness.industrySignificant differenceDNA-PK; Ovarian cancer; PACC; Phase 3 clinical trial; Predictive factors; Antineoplastic Combined Chemotherapy Protocols; DNA-Activated Protein Kinase; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Prognosismedicine.diseasePrognosisPredictive valuePACCCarboplatinhumanitiesFirst line treatmentovarian cancer030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisFemalebusinessOvarian cancerPredictive factorsResearch PaperpACC
researchProduct

Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?

2020

Objective: The therapeutic role of pelvic and para-aortic lymphadenectomy in surgical staging of apparent early-stage epithelial ovarian cancer (eEOC) is still under debate. The aim of this study was to evaluate the potential therapeutic role of systematic lymphadenectomy in patients with eEOC. Methods: Multi-center retrospective cohort study, comparing women with apparent eEOC who underwent comprehensive bilateral pelvic and para-aortic lymphadenectomy (defined as ≥20 lymph nodes) versus patients receiving no lymphadenectomy or lymph node sampling, from 05/1985 to 12/2016. Patients with bulky nodes at CT-scan and those without complete intra-peritoneal surgical staging were excluded. Only …

0301 basic medicinemedicine.medical_specialtyPrognosimedicine.medical_treatmentEarly-stageLymph node samplingCarcinoma Ovarian EpithelialDisease-Free SurvivalPelvisLymph node samplingCohort StudiesSurgical staging03 medical and health sciences0302 clinical medicineOvarian cancerMedicineHumansEpithelial ovarian cancerStage (cooking)early-stage; lymph node sampling; lymphadenectomy; ovarian cancer; prognosis; surgical stagingNeoplasm StagingRetrospective StudiesOvarian NeoplasmsChemotherapybusiness.industryObstetrics and GynecologyRetrospective cohort studyLymphadenectomyMiddle Agedmedicine.diseaseSurvival RateSettore MED/40 - GINECOLOGIA E OSTETRICIA030104 developmental biologyOncology030220 oncology & carcinogenesisLymphatic MetastasisLymph Node ExcisionLymphadenectomyFemaleLymphRadiologyLymph NodesprognosisbusinessOvarian cancer
researchProduct

Dietary restriction: could it be considered as speed bump on tumor progression road?

2016

Dietary restrictions, including fasting (or long-term starvation), calorie restriction (CR), and short-term starvation (STS), are considered a strong rationale that may protect against various diseases, including age-related diseases and cancer. Among dietary approaches, STS, in which food is not consumed during designed fasting periods but is typically not restricted during designated feeding periods, seems to be more suitable, because other dietary regimens involving prolonged fasting periods could worsen the health conditions of cancer patients, being they already naturally prone to weight loss. Until now, the limited amount of available data does not point to a single gene, pathway, or …

0301 basic medicinemedicine.medical_specialtySettore MED/06 - Oncologia MedicaCalorie restrictionCancer cellBiologyBioinformaticsCellular stress response03 medical and health sciencesWeight lossNeoplasmsCellular stress responseInternal medicinemedicineAnimalsHumansChemotherapyShort-term starvationSettore MED/49 - Scienze Tecniche Dietetiche ApplicateCaloric RestrictionStarvationCancerCancer cells; Cellular stress response; Chemotherapy; Diet; Fasting; Short-term starvationFastingGeneral Medicinemedicine.diseaseDietSettore MED/18 - Chirurgia Generale030104 developmental biologyEndocrinologyTumor progressionCancer cellSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratorioSignal transductionmedicine.symptomTumor Biology
researchProduct

Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric canc…

2018

// Gemma Bruera 1, 2 , Silvia Massacese 3 , Antonio Galvano 4 , Antonella Dal Mas 5 , Stefano Guadagni 6, 2 , Giuseppe Calvisi 5 , Eugenio Ciacco 3 , Antonio Russo 4 , Enrico Ricevuto 1, 2 , on behalf of Oncology Network ASL1 Abruzzo, Italy 1 Oncology Territorial Care, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L'Aquila, L'Aquila, Italy 2 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy 3 Pharmacy Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L’Aquila, Italy 4 Medical Oncology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy 5 Pathology, S. Salva…

0301 basic medicinemedicine.medical_specialtySettore MED/06 - Oncologia MedicaDocetaxelNeutropeniametastatic gastric cancerAnd oxaliplatin03 medical and health sciences0302 clinical medicinedocetaxel 5-fluorouracil and oxaliplatinInternal medicinemedicineMucositisdose-finding study5-fluorouracil5-fluorouracil; And oxaliplatin; Docetaxel; Dose-finding study; FD/FOx intensive regimen; First-line triplet chemotherapy; Metastatic gastric cancer; OncologyHypoalbuminemiabusiness.industrymedicine.diseaseOxaliplatinRegimen030104 developmental biologyOncologyDocetaxelFluorouracil030220 oncology & carcinogenesisfirst-line triplet chemotherapyCohortFD/FOx intensive regimenbusinessmedicine.drugResearch PaperOncotarget
researchProduct

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

2019

Background Six months of adjuvant oxaliplatin-based chemotherapy is standard for patients with stage III colon cancer following surgery. However, oxaliplatin is associated with peripheral neurotoxicity which worsens over treatment duration. Consequently, a shorter treatment duration, if equally effective, would be extremely beneficial. A pooled analysis of data for 12 834 stage III colon cancer patients, from six randomised phase III trials of adjuvant therapy, the International Duration Evaluation of Adjuvant chemotherapy study, was carried out and the results presented at the ASCO Annual Meeting 2017. To clarify the potential impact of these results on clinical practice, ESMO decided to s…

0301 basic medicinemedicine.medical_specialtyTime FactorsColorectal cancerRisk AssessmentDisease-Free Survival03 medical and health sciences0302 clinical medicineFOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAdjuvant therapyHumansMulticenter Studies as TopicColectomyNeoplasm StagingRandomized Controlled Trials as Topicbusiness.industryCAPOX RegimenHematologyCongresses as Topicmedicine.diseaseChemotherapy regimenOxaliplatinClinical trialOxaliplatinRegimen030104 developmental biologyOncologyClinical Trials Phase III as TopicChemotherapy Adjuvant030220 oncology & carcinogenesisData Interpretation StatisticalColonic NeoplasmsPractice Guidelines as TopicQuality of LifeNeurotoxicity Syndromesbusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Evaluation of Stem Cell Mobilization in Patients with Multiple Myeloma after Lenalidomide-Based Induction Chemotherapy within the GMMG-HD6 Trial

2016

Abstract Introduction: The German-Speaking Myeloma Multicenter Group (GMMG) has initiated a randomized multicenter phase III trial on the effect of elotuzumab in VRD (bortezomib, lenalidomide, dexamethasone) induction/consolidation and lenalidomide maintenance in patients with newly diagnosed multiple myeloma (GMMG-HD6 trial, NCT02495922). The study compares four cycles induction therapy with VRD vs. VRD + elotuzumab, followed by standard intensification (i.e. mobilization and stem cell transplantation), two cycles consolidation with VRD/VRD + elotuzumab and lenalidomide maintenance +/- elotuzumab. The primary endpoint is determination of the best of four treatment strategies regarding prog…

0301 basic medicinemedicine.medical_specialtybusiness.industryStem cell mobilizationImmunologyInduction chemotherapyCell BiologyHematologymedicine.diseaseBiochemistryTransplantation03 medical and health sciences030104 developmental biologyFamily medicineInduction therapyMedicineIn patientElotuzumabbusinessMultiple myelomamedicine.drugLenalidomideBlood
researchProduct

Chemotherapy in head and neck cancer (I): Management of recurrent or metastatic disease

1992

SummaryThis paper is an up-dated review of the role of systemic chemotherapy in the management of recurrent and/or metastatic head and neck carcinoma.

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatment030106 microbiologyAntineoplastic AgentsDiseaseHead neck cancer03 medical and health sciences0302 clinical medicinemedicineHumansPharmacology (medical)Head and neckHead and neck carcinomaPharmacologyChemotherapybusiness.industrySystemic chemotherapyHead and neck cancerAdvanced stagemedicine.diseaseSurgeryInfectious DiseasesOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisRadiologyNeoplasm Recurrence Localbusiness
researchProduct

Antimicrobial Chemotherapy has a Linear Relationship to the Proportion of Gram-Negative Isolates from Pediatric Burn Wounds.

2018

Wound infection in burns is a relevant cause of morbidity and mortality in children. We aimed to determine the relationship between antibacterial chemotherapy and Gram-negative burn wound colonization and infection. All children admitted to the pediatric intensive care unit for burn trauma from June 1, 2005 to January 31, 2013 were included. We obtained 141 wound samples, of which 88 (65.7%) showed growth of Gram-positive bacteria. Treatment with antimicrobial chemotherapy was necessary in 23 (31.1%) patients. The proportion of Gram-negative isolates seems to increase linear from 12.5% (95% confidence interval (CI): 4.4%-28.7%) without antibacterial chemotherapy to 36.8% (95% CI: 25.5%-49.6…

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatment030106 microbiologyGram-Positive BacteriaPediatrics03 medical and health sciences0302 clinical medicinePharmacotherapyInternal medicineAntimicrobial chemotherapymedicineHumansChildPediatric intensive care unitChemotherapybusiness.industry030208 emergency & critical care medicineOdds ratioAntimicrobialConfidence intervalAnti-Bacterial AgentsLinear relationshipChild PreschoolPediatrics Perinatology and Child HealthWound InfectionbusinessBurnsGram-Negative Bacterial InfectionsKlinische Padiatrie
researchProduct

In Metastatic Non-small cell Lung Cancer Platinum-Based Treated Patients, Herbal Treatment Improves the Quality of Life. A Prospective Randomized Con…

2017

Background: According to clinical experience, Traditional Chinese Medicine (TCM) herbs added to platinum-based therapy (PBT) improve the Quality of Life (QOL) in metastatic non-small cell lung cancer (NSCLC) patients, but this must be prospectively validated.Patients and Methods: Based on clinical impressions regarding the effect of adding TCM herbs to platinum-based chemotherapy, we anticipated that 2 × 21 patients would be sufficient to obtain significant results with an α < 0.05 and power (1 - β) of 90%. To be on the safe side, we enrolled at least 28 patients in each group. In a prospective randomized controlled trial, 61 uniquely defined consecutive patients (PBT+PLACEBO, N = 32; PB…

0301 basic medicinemedicine.medical_specialtyvomitingNauseamedicine.medical_treatmentTraditional Chinese medicinePlaceboGastroenterology03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineMedicineTraditional Chinese MedicinePharmacology (medical)Lung cancerOriginal ResearchPharmacologyChemotherapynon-small cellbusiness.industrylcsh:RM1-950medicine.diseasenauseaSurgerymetastaticClinical triallung cancer030104 developmental biologylcsh:Therapeutics. Pharmacology030220 oncology & carcinogenesisVomitingQuality of Lifemedicine.symptombusinessFrontiers in Pharmacology
researchProduct